ReviewFrontiers in nutrition2022
Curcuminoids for Metabolic Syndrome: Meta-Analysis Evidences Toward Personalized Prevention and Treatment Management.
Review in Frontiers in nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Efficacy of curcumin/turmeric on inflammation and oxidative stress in prediabetes and type 2 diabetes: a systematic review and dose-response meta-analysis.Inflammopharmacology · 2025Pooled it
- Effect of dietary anthocyanins on the risk factors related to metabolic syndrome: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Effects of dietary polyphenol curcumin supplementation on metabolic, inflammatory, and oxidative stress indices in patients with metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2023Pooled it
- Natural Bioactive Compounds Targeting Gut Barrier Integrity and Metabolic Endotoxemia in Cardiometabolic Disease: Mechanistic Insights and Translational Perspectives.Molecules (Basel, Switzerland) · 2026Review
- Functional Foods as Modulators of Epigenetic Mechanisms Affecting Metabolic Health in Adolescence.International journal of molecular sciences · 2026Review
- A combined network pharmacology and experimental approach to investigate the mechanisms of curcumin on diabetes through the adipocytokine signaling pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Review
- Curcumin and Tetrahydrocurcumin as Multi-Organ Modulators of the Adipose Tissue-Gut-Liver Axis: Mechanistic Insights, Therapeutic Potential, and Translational Challenges.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics.Journal of nanobiotechnology · 2025Review
- Gut Microbiota and Cardiovascular Diseases: Unraveling the Role of Dysbiosis and Microbial Metabolites.International journal of molecular sciences · 2025Review
- Natural Products in the Clinical Management of Metabolic Syndrome.Handbook of experimental pharmacology · 2025Review
- The Potential of Natural Products in Metabolic Disease Management: A Thorough Exploration of the Case of Uganda.Endocrine, metabolic & immune disorders drug targets · 2025Review
- Identification of immune and major depressive disorder-related diagnostic markers for early nonalcoholic fatty liver disease by WGCNA and machine learning.Frontiers in bioinformatics · 2025Article
- Soothing the Itch: The Role of Medicinal Plants in Alleviating Pruritus in Palliative Care.Plants (Basel, Switzerland) · 2024Review
- Defining the mechanisms behind the hepatoprotective properties of curcumin.Archives of toxicology · 2024Review
- Mitochondrial Fission as a Therapeutic Target for Metabolic Diseases: Insights into Antioxidant Strategies.Antioxidants (Basel, Switzerland) · 2023Review
- Exploring the Contribution of Curcumin to Cancer Therapy: A Systematic Review of Randomized Controlled Trials.Pharmaceutics · 2023Review
- Review
- Chinese medicinal herbs as potential prodrugs for obesity.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The metabolic syndrome (MS) is a multifactorial syndrome associated with a significant economic burden and healthcare costs. MS management often requires multiple treatments (polydrug) to ameliorate conditions such as diabetes mellitus, insulin resistance, obesity, cardiovascular diseases, hypertension, and non-alcoholic fatty liver disease (NAFLD). However, various therapeutics and possible drug-drug interactions may also increase the risk of MS by altering lipid and glucose metabolism and promoting weight gain. In addition, the medications cause side effects such as nausea, flatulence, bloating, insomnia, restlessness, asthenia, palpitations, cardiac arrhythmias, dizziness, and blurred vision. Therefore, is important to identify and develop new safe and effective agents based on a multi-target approach to treat and manage MS. Natural products, such as curcumin, have multi-modalities to simultaneously target several factors involved in the development of MS. This review discusses the recent preclinical and clinical findings, and up-to-date meta-analysis from Randomized Controlled Trials regarding the effects of curcumin on MS, as well as the metabonomics and a pharma-metabolomics outlook considering curcumin metabolites, the gut microbiome, and environment for a complementary personalized prevention and treatment for MS management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.